Početna › Rak mjehura › Oklahoma
Kliničke studije za Rak mjehura u državi Oklahoma
12 studija za Rak mjehura traži sudionike na lokacijama u državi Oklahoma.
Gradovi u državi Oklahoma
Službeni tekst studije (engleski)
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
- University of Oklahoma Health Sciences Center, Oklahoma City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT07000084Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Oklahoma City, Oklahoma City
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 40 do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT05334069Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT06770582Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT07061964Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT03866382The Vanguard Study: Testing a New Way to Screen for Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 45 do 75 godina · Oba spola · Ažurirano 2. ruj 2026. · NCT06995898FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- University of Oklahoma - Health Sciences Center, Oklahoma City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 20. kol 2026. · NCT05614739Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 18. kol 2026. · NCT07097142A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- OU Health Stephenson Cancer Center, Oklahoma City
- OU Medical Center, Oklahoma City
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 22. srp 2026. · NCT04879329A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 6. srp 2026. · NCT04389632Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Mercy Hospital - OKC, Oklahoma City
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 29. lip 2026. · NCT07327489SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 28. lis 2025. · NCT03452774Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.